Scandion Oncology announces that the Clinical Trial Application for a pancreatic cancer study with chemotherapy and SCO-101 has been submitted to the Danish Medicines Agency and the Ethical Committee.

Scandion Oncology A/S (“Scandion Oncology”) is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Danish Medicines Agency and the Ethical Committee. A response is expected within 60 days.

The release as fetched from its publisher. scandiononcology.com ↗